摘要
目的:探讨抗精神病药治疗对外周血单核细胞miRNA-92a-3p表达的影响。方法:给予26例汉族精神分裂症患者(患者组)非典型抗精神病药(奥氮平、喹硫平、氯氮平、利培酮、齐拉西酮、阿立哌唑)单药治疗12周;治疗前后使用阳性和阴性症状量表(PANSS)评估临床症状;采用实时定量荧光PCR检测外周血单核细胞内miRNA-92a-3p相对表达水平,并与48名正常者(对照组)比较;分析治疗前后PANSS评分与miRNA-92a-3p的相对表达量变化的关系。结果:患者组治疗前后外周血单核细胞内miRNA-92a-3p相对表达量明显高于对照组(P均<0.01),且治疗后显著高于治疗前(P<0.05);患者组治疗前后miRNA-92a-3p相对表达量变化与PANSS总分变化无相关性。结论:精神分裂症患者外周血单核细胞miRNA-92a-3p相对表达量增高,抗精神病药治疗进一步提高其表达水平。
Objective:To explore the effect of antipsychotic treatment on the expression of miRNA-92a-3p in peripheral blood mononuclear cells.Method:26 cases of Han schizophrenia(patient group)were given atypical antipsychotics(olanzapine,quetiapine,clozapine,risperidone,ziprasidone,aripiprazole)monotherapy 12 Weeks;use the Positive and Negative Symptom Scale(PANSS)to assess clinical symptoms before and after treatment;real-time quantitative fluorescent PCR was used to detect the relative expression levels of miRNA-92a-3p in peripheral blood mononuclear cells between the two groups,and compared with 48 normal subjects(normal control group);analysis of the relationship between the PANSS score and the relative expression of miRNA-92a-3p before and after treatment.Results:The relative expression of miRNA-92a-3p in peripheral blood mononuclear cells in the patient group before and after treatment was significantly higher than that in the normal control group(all P<0.01),and after treatment was significantly higher than before treatment(P<0.05);in the patient group the changes in the relative expression of miRNA-92a-3p before and after treatment had no correlation with the changes in the total PANSS score.Conclusion:The relative expression level of miRNA-92a-3p in peripheral blood mononuclear cells of patients with schizophrenia is increased,and antipsychotic treatment further increases its expression level.
作者
陆雅娜
王国强
张付全
殷嘉浚
LU Ya-na;WANG Guo-qiang;ZHANG Fu-quan;YIN Jia-jun(Wuxi Mental Health Center affiliated to Nanjing Medical University,Wuxi 214000,China)
出处
《临床精神医学杂志》
CAS
2021年第4期306-308,共3页
Journal of Clinical Psychiatry
基金
无锡市科技发展资金项目(WX18IIAN033)。